HRP20170403T1 - SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA - Google Patents
SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA Download PDFInfo
- Publication number
- HRP20170403T1 HRP20170403T1 HRP20170403TT HRP20170403T HRP20170403T1 HR P20170403 T1 HRP20170403 T1 HR P20170403T1 HR P20170403T T HRP20170403T T HR P20170403TT HR P20170403 T HRP20170403 T HR P20170403T HR P20170403 T1 HRP20170403 T1 HR P20170403T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound according
- alkyl
- hydrogen
- linked
- Prior art date
Links
- 102000002689 Toll-like receptor Human genes 0.000 title 1
- 108020000411 Toll-like receptor Proteins 0.000 title 1
- 150000008038 benzoazepines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 10
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Claims (15)
1. Spoj s formulom I, ili njegova farmaceutski prihvatljiva sol:
[image]
,
naznačen time što
[image]
je dvostruka veza ili jednostruka veza;
R2 i R3 se neovisno bira između H i C1-C6 alkila, ili su R2 i R3 povezani kako bi tvorili zasićeni 3 do 7-eročlani karbocikl;
jedan od R7 i R8 je
[image]
ili
[image]
,
a drugi je vodik;
R4 je -NRcRd ili -OR10;
Rc i Rd su C1-C6 alkil, koji može biti supstituiran s jednim ili više -OH;
R10 je C1-C12 alkil, koji može biti supstituiran s jednim ili više -OH;
Z je C i
[image]
je dvostruka veza, ili Z je N, a
[image]
je jednostruka veza;
Ra i Rb se neovisno bira između H, C1-C12 alkila, C2-C10 alkenila, C2-C12 alkinila i Re, gdje C1-C12 alkil može biti supstituiran s jednim ili više -OR10, ili Re;
Re se bira između -NH2, -NH(C1-C12 alkil) i -N(C1-C12 alkil)2;
R1 je odsutan kada
[image]
je dvostruka veza, ili kada
[image]
je jednostruka veza, N1-R1 i jedan od Ra ili Rb su povezani kako bi tvorili zasićeni, djelomično nezasićeni ili nezasićeni 5-7-eročlani heterociklički prsten, a drugi od Ra ili Rb može biti vodik ili je po potrebi odsutan zbog nezasićenosti prstena; i
gdje vrijedi najmanje jedna od slijedećih točaka A-D:
A) R7 nije vodik;
B) R8 nije vodik i najmanje jedan od Ra i Rb nije vodik;
C) Z je N; ili
D) N1-R1 i jedan od Ra ili Rb su povezani kako bi tvorili zasićeni, djelomično nezasićeni ili nezasićeni 5-7-eročlani heterociklički prsten.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R7
[image]
ili
[image]
.
3. Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time što najmanje jedan od Ra i Rb nije vodik; ili je jedan od Ra i Rb C1-C12 alkil, a drugi od Ra i Rb je vodik; ili je jedan od Ra i Rb C1-C12 alkil, supstituiran s Re; ili su Ra i Rb oba C1-C12 alkil; ili je jedan od Ra i Rb Re, a drugi od Ra i Rb je vodik.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R8 nije vodik.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što su N1 i jedan od Ra ili Rb povezani kako bi tvorili zasićeni, djelomično nezasićeni ili nezasićeni 5-7-eročlani heterociklički prsten, a drugi od Ra ili Rb je vodik ili je po potrebi odsutan zbog nezasićenosti prstena.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što su N1 i jedan od Ra ili Rb povezani kako bi tvorili zasićeni, djelomično nezasićeni ili nezasićeni 5-eročlani heterociklički prsten.
7. Spoj u skladu s patentnim zahtjevom 6, naznačen time što su N1 i jedan od Ra ili Rb povezani kako bi tvorili
[image]
ili
[image]
.
8. Spoj u skladu s patentnim zahtjevom 1, naznačen time što najmanje jedan od R2 i R3 nije vodik; ili su R2 i R3 povezani kako bi tvorili zasićeni karbocikl.
9. Spoj u skladu s patentnim zahtjevom 8, naznačen time što su R2 i R3 povezani kako bi tvorili ciklopropil.
10. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je Z N.
11. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R4 -OR10, a R10 je alkil; ili je R4 -NRcRd, a Rc i Rd su oba alkil.
12. Spoj u skladu s patentnim zahtjevom 11, naznačen time što je R4 -O-etil ili -N(propil)2.
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira između
[image]
[image]
ili njihovih farmaceutski prihvatljivih soli.
14. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1-13 ili, njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljiv razrjeđivač ili podlogu.
15. Spoj u skladu s bilo kojim od patentnih zahtjeva 1-13 ili, njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju stanja koje se bira između raka, bolesti povezane s imunosnim kompleksom, autoimune bolesti, zarazne bolesti, upalnog poremećaja, imunodeficijencije, odbacivanja presatka, reakcije presatka prema domaćinu, alergije, kardiovaskularne bolesti, fibrotične bolesti, astme i sepse.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161432070P | 2011-01-12 | 2011-01-12 | |
EP12733896.0A EP2663555B1 (en) | 2011-01-12 | 2012-01-12 | Substituted benzoazepines as toll-like receptor modulators |
PCT/US2012/021116 WO2012097177A2 (en) | 2011-01-12 | 2012-01-12 | Substituted benzoazepines as toll-like receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170403T1 true HRP20170403T1 (hr) | 2017-05-19 |
Family
ID=46507673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170403TT HRP20170403T1 (hr) | 2011-01-12 | 2017-03-10 | SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA |
Country Status (15)
Country | Link |
---|---|
US (1) | US20140088085A1 (hr) |
EP (2) | EP3207930A1 (hr) |
JP (2) | JP5985510B2 (hr) |
CN (2) | CN103562201B (hr) |
AU (1) | AU2012205490B2 (hr) |
BR (1) | BR112013017947A2 (hr) |
CA (1) | CA2824786A1 (hr) |
DK (1) | DK2663555T3 (hr) |
ES (1) | ES2620605T3 (hr) |
HR (1) | HRP20170403T1 (hr) |
HU (1) | HUE032638T2 (hr) |
MX (1) | MX348935B (hr) |
PL (1) | PL2663555T4 (hr) |
PT (1) | PT2663555T (hr) |
WO (1) | WO2012097177A2 (hr) |
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2663550B1 (en) * | 2011-01-12 | 2016-12-14 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN105899537A (zh) | 2014-01-10 | 2016-08-24 | 博笛生物科技(北京)有限公司 | 靶向表达egfr的肿瘤的化合物和组合物 |
US10413565B2 (en) | 2014-04-30 | 2019-09-17 | Northwestern University | Nanostructures for modulating intercellular communication and uses thereof |
TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
CN112546231A (zh) | 2014-07-09 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
CA2954446A1 (en) | 2014-07-09 | 2016-01-14 | Shanghai Birdie Biotech, Inc. | Anti-pd-l1 combinations for treating tumors |
PE20170694A1 (es) | 2014-10-06 | 2017-05-26 | Exicure Inc | Compuestos anti-tnf |
JP6644792B2 (ja) * | 2014-12-18 | 2020-02-12 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンザゼピンスルホンアミド化合物 |
US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
SI3265458T1 (sl) * | 2015-03-06 | 2019-03-29 | F. Hoffmann-La Roche Ag | Benzazepin dikarboksamidne spojine |
WO2016149323A1 (en) * | 2015-03-16 | 2016-09-22 | Exicure, Inc. | Immunomodulatory spherical nucleic acids |
JP2018525412A (ja) | 2015-08-26 | 2018-09-06 | ギリアード サイエンシーズ, インコーポレイテッド | 重水素化トール様受容体調節因子 |
CN114848812A (zh) | 2015-12-15 | 2022-08-05 | 吉利德科学公司 | 人免疫缺陷病毒中和抗体 |
CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
LT3453707T (lt) * | 2016-05-06 | 2022-03-10 | Shanghai De Novo Pharmatech Co., Ltd. | Benzazepino darinys, gamybos būdas, farmacinė kompozicija ir jos naudojimas |
BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
JP6770098B2 (ja) | 2016-05-27 | 2020-10-14 | ギリアード サイエンシーズ, インコーポレイテッド | Ns5a、ns5bまたはns3阻害剤を使用する、b型肝炎ウイルス感染症を処置するための方法 |
US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
EA038972B1 (ru) | 2016-07-30 | 2021-11-16 | Бристол-Маерс Сквибб Компани | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 |
JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
WO2018045144A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
US10660877B2 (en) | 2016-09-09 | 2020-05-26 | Bristol-Myers Squibb Company | Pyridyl substituted indole compounds |
AU2017342536A1 (en) | 2016-10-14 | 2019-05-02 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome |
TWI784370B (zh) | 2017-01-31 | 2022-11-21 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
BR112019019116A2 (pt) | 2017-03-15 | 2020-05-05 | Silverback Therapeutics Inc | compostos de benzazepina, conjugados, e usos dos mesmos |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
JP7080501B2 (ja) | 2017-06-23 | 2022-06-06 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 医薬品組成物 |
JP7104775B2 (ja) | 2017-08-04 | 2022-07-21 | ブリストル-マイヤーズ スクイブ カンパニー | Tlr7/8/9の阻害剤として有用な置換インドール化合物 |
WO2019028301A1 (en) | 2017-08-04 | 2019-02-07 | Bristol-Myers Squibb Company | INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL |
AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
US11040033B2 (en) | 2017-08-22 | 2021-06-22 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
CN109694351B (zh) * | 2017-10-23 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 苯并氮杂*衍生物、其制备方法及其在医药上的应用 |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
JP7265554B2 (ja) | 2017-11-14 | 2023-04-26 | ブリストル-マイヤーズ スクイブ カンパニー | 置換インドール化合物 |
AU2018385693A1 (en) | 2017-12-15 | 2020-06-18 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
SI3728252T1 (sl) | 2017-12-18 | 2023-11-30 | Bristol-Myers Squibb Company | 4-azaindolne spojine |
JP7304352B2 (ja) | 2017-12-19 | 2023-07-06 | ブリストル-マイヤーズ スクイブ カンパニー | 6-アザインドール化合物 |
SG11202005700SA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Amide substituted indole compounds useful as tlr inhibitors |
ES2932361T3 (es) | 2017-12-19 | 2023-01-18 | Bristol Myers Squibb Co | Compuestos de indol sustituidos útiles como inhibidores de TLR |
KR20200100760A (ko) | 2017-12-20 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | 디아자인돌 화합물 |
SG11202005694RA (en) | 2017-12-20 | 2020-07-29 | Bristol Myers Squibb Co | Amino indole compounds useful as tlr inhibitors |
ES2965182T3 (es) | 2017-12-20 | 2024-04-11 | Bristol Myers Squibb Co | Compuestos de indol sustituidos con arilo y heteroarilo |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
KR102492187B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드 |
EP4227302A1 (en) | 2018-02-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
EP4253366A3 (en) | 2018-02-16 | 2023-11-29 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
CN111788204B (zh) | 2018-02-26 | 2023-05-05 | 吉利德科学公司 | 作为hbv复制抑制剂的取代吡咯嗪化合物 |
WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
US11168130B2 (en) | 2018-07-03 | 2021-11-09 | Gilead Sciences, Inc. | Antibodies that target HIV GP120 and methods of use |
EP3818052A1 (en) | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
AU2019297428C1 (en) | 2018-07-06 | 2023-03-23 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
PT3820572T (pt) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Inibidores pd-1/pd-l1 |
CN112423750A (zh) | 2018-07-16 | 2021-02-26 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
EP3849615A1 (en) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
US20220048895A1 (en) * | 2018-09-12 | 2022-02-17 | Silverback Therapeutics, Inc. | Substituted benzazepine compounds, conjugates, and uses thereof |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
CN113543851A (zh) | 2019-03-07 | 2021-10-22 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
EP3935066A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
SG11202110401WA (en) * | 2019-04-09 | 2021-10-28 | Hoffmann La Roche | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
KR20220035908A (ko) | 2019-06-19 | 2022-03-22 | 실버백 테라퓨틱스, 인크. | 항-메소텔린 항체 및 이의 면역접합체 |
CN114245807A (zh) | 2019-06-25 | 2022-03-25 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
BR112022002720A2 (pt) | 2019-08-15 | 2022-10-11 | Silverback Therapeutics Inc | Formulações de conjugados de benzazepinas e usos das mesmas |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
WO2021067181A1 (en) | 2019-09-30 | 2021-04-08 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
AU2020374947A1 (en) | 2019-10-31 | 2022-03-31 | Forty Seven, Inc. | Anti-CD47 and anti-CD20 based treatment of blood cancer |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
JP2023502530A (ja) | 2019-11-26 | 2023-01-24 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv予防のためのカプシド阻害剤 |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
AU2020412875A1 (en) | 2019-12-24 | 2022-06-23 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
MX2022009947A (es) | 2020-02-14 | 2022-11-07 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
JP2023518433A (ja) | 2020-03-20 | 2023-05-01 | ギリアード サイエンシーズ, インコーポレイテッド | 4’-c-置換-2-ハロ-2’-デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法 |
CN115698009A (zh) | 2020-05-01 | 2023-02-03 | 吉利德科学公司 | 抑制cd73的2,4-二氧代嘧啶化合物 |
EP4153181A1 (en) | 2020-05-21 | 2023-03-29 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
EP4172157A1 (en) | 2020-06-25 | 2023-05-03 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of hiv |
AU2021300362A1 (en) | 2020-07-01 | 2023-02-23 | ARS Pharmaceuticals, Inc. | Anti-ASGR1 antibody conjugates and uses thereof |
JP2023536945A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 動力学的に作用するアジュバントアンサンブル |
CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体7または8作用薬と機能性薬物の結合体およびその用途 |
CR20230071A (es) | 2020-08-07 | 2023-04-11 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico |
TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
US20220144923A1 (en) | 2020-11-11 | 2022-05-12 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
EP4319820A1 (en) | 2021-04-10 | 2024-02-14 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
IL309378A (en) | 2021-06-23 | 2024-02-01 | Gilead Sciences Inc | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
US20230203071A1 (en) | 2021-12-03 | 2023-06-29 | Zhimin Du | Therapeutic compounds for hiv virus infection |
WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202337439A (zh) | 2021-12-03 | 2023-10-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
ATE216366T1 (de) * | 1996-08-16 | 2002-05-15 | Pfizer | 2-aminobenzazepin-derivate und ihre verwendung für die behandlung von immunosuppression |
TWI404537B (zh) * | 2005-08-19 | 2013-08-11 | Array Biopharma Inc | 作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯 |
CA2742863C (en) * | 2008-11-06 | 2017-05-09 | Ventirx Pharmaceuticals, Inc. | Methods of synthesis of benzazepine derivatives |
EP2663550B1 (en) * | 2011-01-12 | 2016-12-14 | VentiRx Pharmaceuticals, Inc. | Substituted benzoazepines as toll-like receptor modulators |
-
2012
- 2012-01-12 US US13/979,634 patent/US20140088085A1/en not_active Abandoned
- 2012-01-12 PT PT127338960T patent/PT2663555T/pt unknown
- 2012-01-12 BR BR112013017947A patent/BR112013017947A2/pt not_active Application Discontinuation
- 2012-01-12 CN CN201280012944.XA patent/CN103562201B/zh not_active Expired - Fee Related
- 2012-01-12 CA CA2824786A patent/CA2824786A1/en not_active Abandoned
- 2012-01-12 MX MX2013008220A patent/MX348935B/es active IP Right Grant
- 2012-01-12 AU AU2012205490A patent/AU2012205490B2/en not_active Ceased
- 2012-01-12 PL PL12733896T patent/PL2663555T4/pl unknown
- 2012-01-12 JP JP2013549549A patent/JP5985510B2/ja active Active
- 2012-01-12 DK DK12733896.0T patent/DK2663555T3/en active
- 2012-01-12 ES ES12733896.0T patent/ES2620605T3/es active Active
- 2012-01-12 HU HUE12733896A patent/HUE032638T2/en unknown
- 2012-01-12 EP EP16203755.0A patent/EP3207930A1/en not_active Withdrawn
- 2012-01-12 CN CN201610859766.4A patent/CN106518851A/zh active Pending
- 2012-01-12 EP EP12733896.0A patent/EP2663555B1/en active Active
- 2012-01-12 WO PCT/US2012/021116 patent/WO2012097177A2/en active Application Filing
-
2016
- 2016-08-03 JP JP2016152504A patent/JP6192027B2/ja active Active
-
2017
- 2017-03-10 HR HRP20170403TT patent/HRP20170403T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2012097177A3 (en) | 2012-10-26 |
CN103562201B (zh) | 2016-10-19 |
MX2013008220A (es) | 2014-01-20 |
CN103562201A (zh) | 2014-02-05 |
PL2663555T3 (pl) | 2017-08-31 |
EP2663555A2 (en) | 2013-11-20 |
JP6192027B2 (ja) | 2017-09-06 |
CN106518851A (zh) | 2017-03-22 |
JP5985510B2 (ja) | 2016-09-06 |
EP3207930A1 (en) | 2017-08-23 |
EP2663555B1 (en) | 2016-12-14 |
CA2824786A1 (en) | 2012-07-19 |
DK2663555T3 (en) | 2017-03-27 |
EP2663555A4 (en) | 2014-07-16 |
MX348935B (es) | 2017-07-03 |
AU2012205490A1 (en) | 2013-08-29 |
PL2663555T4 (pl) | 2017-08-31 |
JP2016199582A (ja) | 2016-12-01 |
BR112013017947A2 (pt) | 2018-12-18 |
ES2620605T3 (es) | 2017-06-29 |
JP2014503556A (ja) | 2014-02-13 |
WO2012097177A2 (en) | 2012-07-19 |
PT2663555T (pt) | 2017-03-23 |
HUE032638T2 (en) | 2017-10-30 |
US20140088085A1 (en) | 2014-03-27 |
AU2012205490B2 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170403T1 (hr) | SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA | |
HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
HRP20170401T1 (hr) | SUPSTITUIRANI BENZOAZEPINI KAO MODULATORI TOLL-u SLIČNIH RECEPTORA | |
HRP20120830T1 (hr) | Imidazolkarboksamidi | |
NZ627878A (en) | P2x4 receptor antagonist | |
AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
EA201290940A1 (ru) | Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами | |
RS52510B (en) | INSECTICIDE COMPOUNDS | |
AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
JP2011105738A5 (hr) | ||
RS53610B1 (en) | ANTAGONIST PIPERIDINONE CARBOXAMID AZAINDAN CGRP RECEPTORA | |
GEP201606526B (en) | 5-ht3 receptor antagonists | |
ES2586527T3 (es) | Compuestos heterocíclicos y uso de los mismos como moduladores del receptor de tirosina quinasas de tipo III | |
JP2013532130A5 (hr) | ||
DOP2014000287A (es) | Compuestos de fenoxietil piperidina | |
EA201200602A1 (ru) | Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1 | |
EA201400854A1 (ru) | 4-(бензоимидазол-2-ил)тиазольные соединения и родственные аза производные | |
HRP20160523T1 (hr) | Antikancerozni steroidni laktoni, nezasićeni na položaju 7(8) | |
AR090112A1 (es) | Sulfinilaminobenzamidas efectivas como herbicidas | |
FR2975917B1 (fr) | Dispositif de generation de mousse d'une lance a incendie | |
SMT201600012B (it) | Composti eterociclici come leganti del recettore h3 dell'istamina | |
DK2603206T3 (da) | Farmaceutiske sammensætninger af metabotrofisk glutamat 5 receptor (mglu5)-antagonister | |
FR2958515B1 (fr) | Dispositif support d'assiettes | |
ES2659974T3 (es) | Compuestos de isotiazolina sustituidos con tiofeno o furano como pesticidas | |
PH12014502845A1 (en) | Novel cholecystokinin receptor ligands |